Actively Recruiting
The Effects of Social Isolation and Social Interaction on the Risk of Dementia Progression and Brain Function in SCD (Subjective Cognitive Decline, SCD)
Led by The First Affiliated Hospital with Nanjing Medical University · Updated on 2024-03-28
209
Participants Needed
1
Research Sites
252 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn about the effects of social isolation and social interaction on the risk of dementia progression and brain function in SCD 1. To explore the association between social isolation and lonely SCD populations and the occurrence and progression of MCI and AD through cross-sectional studies, cohort studies and randomized controlled trials of SCD; 2. To clarify the correlation between different carrier states, resting brain function connectivity characteristics, and dual-task walking ability of APOEε4 allele and the progression of SCD to MCI and AD during the cognitive progress of people with SCD affected by social isolation; 3. Establish a predictive model of cognitive decline from SCD to MCI and AD, and apply it to the SCD population to carry out individualized interventions; 4. Confirm the protective effect of social interaction on cognitive level and brain function in SCD patients.
CONDITIONS
Official Title
The Effects of Social Isolation and Social Interaction on the Risk of Dementia Progression and Brain Function in SCD (Subjective Cognitive Decline, SCD)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Self-perceived continuous cognitive decline compared with previous normal state, not related to acute events
- Normal standard cognitive test after adjusting for age, gender, and education, or does not meet Mild Cognitive Impairment diagnostic criteria
- Able to sign the informed consent form themselves
- Age between 45 and 85 years
- Diagnosis of Subjective Cognitive Decline (SCD)
You will not qualify if you...
- Age under 45 years or over 85 years
- Diagnosis of vascular dementia or other central nervous system diseases
- Hachinski Ischemic Scale score greater than 4 points
- Unable to complete neuropsychological tests due to blindness, deafness, or severe language impairment
- Drug abuse or alcohol dependency within the last 6 months
- Current participation in other cognition studies
- Severe diabetes mellitus, cardiovascular disease, cerebrovascular disease, liver disease, kidney disease, or psychiatric disorders
- Contraindications to imaging techniques including claustrophobia, metallic implants, or electronic devices like cardiac pacemakers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Nanjing Medical University
Nanjing, China, Jiangsu, China, 210000
Actively Recruiting
Research Team
Z
Zhu Yi
CONTACT
S
Shi Chunxu
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here